Supplementary Table 1. Summary of regional PET retention data at baseline.

Supplementary Table 2. Summary of group-level statistical tests for (A) ^{11}C-PiB, (B) ^{11}C-DED, (C) ^{18}F-FDG.

Supplementary Table 3. Sensitivity analysis of statistical tests in Supplementary Table 2.

Supplementary Table 4. Results from voxel-wise SPM8 comparisons of the pMC group versus the Control group and PiB+ MCI groups.

Supplementary Figure 1. Time course of baseline and longitudinal regional ^{11}C-PiB, ^{11}C-DED and ^{18}F-FDG uptake in sporadic PiB+ MCI patients in the posterior cingulate cortex region of interest. Baseline and follow-up PET uptake of (**A**) ^{11}C-PiB, (**B**) ^{11}C-DED and (**C**) ^{18}F-FDG in the posterior cingulate cortex of patients with sporadic PiB+ MCI with respect to the time from MCI diagnosis. Symbols: Grey dots = PiB+ MCI patients; black dots = patients who converted to Alzheimer's disease. The horizontal axis represents time since the diagnosis of MCI in years.

AD = Alzheimer's disease; DED = ^{11}C-deuterium-L-deprenyl; FDG = ^{18}F-fluorodeoxyglucose; MCI = mild cognitive impairment; PiB = ^{11}C-Pittsburgh Compound-B; SUVR = standardized uptake value ratio.